Characterization of type-specific HPV prevalence in a population of persistent cutaneous warts in Flanders, Belgium.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 10 2023
Historique:
received: 30 05 2023
accepted: 04 10 2023
medline: 23 10 2023
pubmed: 16 10 2023
entrez: 15 10 2023
Statut: epublish

Résumé

Cutaneous warts are benign skin lesions caused by the human papillomavirus (HPV). Even though they are considered benign, they can have a considerable impact on the quality of life and cause serious illness in certain immunocompromised populations. Studies have shown that the efficacy of wart treatment is dependent on the causative HPV type. Therefore, in this article, we aim to determine the HPV genotype-specific prevalence in cutaneous warts of a Flemish population as part of the Omnivirol-Salycilic acid randomized controlled trial. Swab samples of cutaneous warts (n = 269) were collected during enrollment. The DNA extraction was performed on the automated NucliSENS® easyMAG® system (bioMérieux). The samples were analyzed with two separate in-house PCR assays capable of detecting the most prevalent cutaneous HPV types (i.e. wart-associated HPV qPCR) as well as the most relevant mucosal types (i.e. RIATOL qPCR assay). In total, the type-specific prevalence of 30 distinct HPV genotypes was determined. The beta-globin gene was used as a cellularity control and for viral load quantification. Data concerning wart persistence, previous treatment, wart type, and other relevant wart and patient characteristics was collected through a baseline questionnaire. The study population consisted mostly of persistent warts considering that 98% (n = 263) of the sampled skin lesions were older than six months and 92% (n = 247) had undergone previous treatment. The most prominent wart type was the mosaic verruca plantaris (42%, n = 113). The most prevalent HPV types were cutaneous HPV types 27 (73%, n = 195), 57 (63%, n = 169), and 2 (42%, n = 113). Only 2% (n = 6) of the lesions was HPV negative. The highest median viral loads were observed with HPV27 and 57 (i.e. 6.29E+04 and 7.47E+01 viral copies per cell respectively). The multivariate analysis found significant associations between wart persistence and certain wart types, the number of warts, and HPV genotypes. Based on these findings, persistent warts are more likely to: (1) be verruca vulgaris, verruca plantaris simple or mosaic, (2) to manifest as multiple warts, (3) and to be negative for HPV type 2 or 4. These characteristics can be useful in the clinical setting for future risk stratification when considering treatment triage and management. Trial registration: NCT05862441, 17/05/2023 (retrospectively registered).

Identifiants

pubmed: 37840107
doi: 10.1038/s41598-023-44154-y
pii: 10.1038/s41598-023-44154-y
pmc: PMC10577142
doi:

Substances chimiques

DNA, Viral 0

Banques de données

ClinicalTrials.gov
['NCT05862441']

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17492

Informations de copyright

© 2023. Springer Nature Limited.

Références

Clin Med Res. 2006 Dec;4(4):273-93
pubmed: 17210977
J Clin Microbiol. 2010 May;48(5):1706-11
pubmed: 20237103
J Clin Med. 2015 Apr 24;4(5):832-46
pubmed: 26239450
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
BMJ Open. 2015 Nov 24;5(11):e009406
pubmed: 26603251
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Br J Dermatol. 2015 Jan;172(1):196-201
pubmed: 24976535
J Clin Microbiol. 2012 Dec;50(12):4073-7
pubmed: 23052314
Br J Dermatol. 2001 Jan;144(1):4-11
pubmed: 11167676
Ann Fam Med. 2013 Sep-Oct;11(5):437-41
pubmed: 24019275
J Clin Microbiol. 2011 Sep;49(9):3262-7
pubmed: 21813725
Br J Dermatol. 2003 Dec;149(6):1192-9
pubmed: 14674896
Qual Quant. 2018;52(4):1957-1976
pubmed: 29937587
Br J Dermatol. 2009 Sep;161(3):528-35
pubmed: 19519829
Pediatr Dermatol. 2013 Nov-Dec;30(6):730-5
pubmed: 24283440
Arch Dermatol. 1963 Mar;87:306-10
pubmed: 13933441
Acta Dermatovenerol Alp Pannonica Adriat. 2011 Sep;20(3):145-54
pubmed: 22131115
J Invest Dermatol. 1986 Aug;87(2):236-8
pubmed: 3016103
BMJ. 2014 May 27;348:g3339
pubmed: 24865780
Contemp Clin Trials Commun. 2020 Jan 21;17:100534
pubmed: 32211559
Clin Podiatr Med Surg. 2016 Jul;33(3):337-53
pubmed: 27215155
J Clin Virol. 2013 Jul;57(3):227-32
pubmed: 23518443
J Clin Virol. 2011 Oct;52(2):84-7
pubmed: 21798797
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001781
pubmed: 16855978
J Clin Virol. 2019 Nov;120:57-62
pubmed: 31569008
Psychol Methods. 2001 Dec;6(4):330-51
pubmed: 11778676
J Clin Virol. 2012 Nov;55(3):250-5
pubmed: 22884670
BMJ. 2011 Jun 07;342:d3271
pubmed: 21652750
Am Fam Physician. 2005 Aug 15;72(4):647-52
pubmed: 16127954
Ther Adv Infect Dis. 2023 Aug 4;10:20499361231190224
pubmed: 37547268
J Clin Microbiol. 2011 Oct;49(10):3560-7
pubmed: 21832015
Front Cell Infect Microbiol. 2020 Jan 24;10:4
pubmed: 32039037
Biomed Environ Sci. 2009 Feb;22(1):55-61
pubmed: 19462689
Clin Chem Lab Med. 2011 Dec 20;50(4):655-61
pubmed: 22505529
J Med Virol. 2022 Jun;94(6):2897-2901
pubmed: 34890486
Br J Dermatol. 2014 Oct;171(4):696-712
pubmed: 25273231
Viruses. 2022 Oct 15;14(10):
pubmed: 36298821
Clin Microbiol Rev. 2003 Jan;16(1):1-17
pubmed: 12525422
Virology. 2013 Oct;445(1-2):224-31
pubmed: 23928291
J Clin Pathol. 1998 Aug;51(8):606-10
pubmed: 9828820
Pediatr Dermatol. 2015 Sep-Oct;32(5):679-83
pubmed: 25879618
Br J Dermatol. 2018 Jan;178(1):253-260
pubmed: 28646591
J Med Virol. 2021 Jun;93(6):3841-3848
pubmed: 33090508

Auteurs

Nina Redzic (N)

Laboratory of Molecular Diagnostics, AML - Sonic Healthcare Benelux, Antwerp, Belgium. nina.redzic@aml-lab.be.
AMBIOR, Laboratory for Cell Biology and Histology, University of Antwerp, Antwerp, Belgium. nina.redzic@aml-lab.be.

A Rita Pereira (AR)

Laboratory of Molecular Diagnostics, AML - Sonic Healthcare Benelux, Antwerp, Belgium.

Sonia Menon (S)

International Centre for Reproductive Health, Ghent University, Ghent, Belgium.

Johannes Bogers (J)

Laboratory of Molecular Diagnostics, AML - Sonic Healthcare Benelux, Antwerp, Belgium.
AMBIOR, Laboratory for Cell Biology and Histology, University of Antwerp, Antwerp, Belgium.
National Reference Centre for HPV, Brussels, Belgium.
Department of Obstetrics and Gynecology, Women's Clinic, Ghent University Hospital, Ghent, Belgium.

Astrid Coppens (A)

Laboratory of Molecular Diagnostics, AML - Sonic Healthcare Benelux, Antwerp, Belgium.

Kaat Kehoe (K)

Laboratory of Molecular Diagnostics, AML - Sonic Healthcare Benelux, Antwerp, Belgium.
National Reference Centre for HPV, Brussels, Belgium.

Davy Vanden Broeck (D)

Laboratory of Molecular Diagnostics, AML - Sonic Healthcare Benelux, Antwerp, Belgium.
AMBIOR, Laboratory for Cell Biology and Histology, University of Antwerp, Antwerp, Belgium.
International Centre for Reproductive Health, Ghent University, Ghent, Belgium.
National Reference Centre for HPV, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH